Skip to content
10-Q

Quarterly Report

Odyssey Therapeutics, Inc. ODTX

0001193125-26-274290

← back to feed
Filed
Jun 17, 2026 4:45 PM ET
Period of report
Jun 12, 2026

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Jun 12, 2026 48.03M sh
Shares Diluted Q1 2026 · Mar 31, 2026 5.66M sh
Shares Diluted Q1 2026 · Mar 31, 2025 976.15K sh
Capex Q1 2026 · Mar 31, 2026 $148K
Capex Q1 2026 · Mar 31, 2025 $927K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$41.04M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$38.62M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $35.72M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $41.69M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $54.91M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$523.69M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$488.28M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$417.17M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$382.53M
Current Liabilities Q1 2026 · Mar 31, 2026 $22.21M
Current Liabilities Q1 2026 · Dec 31, 2025 $26.48M
Total Liabilities Q1 2026 · Mar 31, 2026 $49.21M
Total Liabilities Q1 2026 · Dec 31, 2025 $54.51M
Current Assets Q1 2026 · Mar 31, 2026 $185.1M
Current Assets Q1 2026 · Dec 31, 2025 $190.66M
Total Assets Q1 2026 · Mar 31, 2026 $229.07M
Total Assets Q1 2026 · Dec 31, 2025 $269.79M
Eps Diluted Q1 2026 · Mar 31, 2026 −$6.77
Eps Diluted Q1 2026 · Mar 31, 2025 −$39.37
Eps Basic Q1 2026 · Mar 31, 2026 −$6.77
Eps Basic Q1 2026 · Mar 31, 2025 −$39.37
Sga Expense Q1 2026 · Mar 31, 2026 $7.35M
Sga Expense Q1 2026 · Mar 31, 2025 $7.95M
Rd Expense Q1 2026 · Mar 31, 2026 $32.32M
Rd Expense Q1 2026 · Mar 31, 2025 $38.77M
Net Income Q1 2026 · Mar 31, 2026 −$38.26M
Net Income Q1 2026 · Mar 31, 2025 −$38.44M
Operating Income Q1 2026 · Mar 31, 2026 −$39.78M
Operating Income Q1 2026 · Mar 31, 2025 −$39.16M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $1.92M